Related Experiment Video
Updated: Jul 14, 2026
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Management of chronic hepatitis B: consensus guidelines
Morris Sherman1, Stephen Shafran, Kelly Burak
1Department of Medicine, University of Toronto, Toronto General Hospital, Toronto, Canada. morris.sherman@uhn.on.ca
Abstract:
The present document presents the proceedings of the consensus development conference on the management of viral hepatitis held in January 2007 under the auspices of the Canadian Association for the Study of the Liver and the Association of Medical Microbiology and Infectious Disease Canada. Several new agents have become available since the last such document was published in 2004, and new information has become available to help assess risk of adverse outcomes and who should be treated. In addition, the participants at the meeting identified a number of structural barriers that exist uniquely in Canada and that prevent physicians from properly managing their patients. The conference discussed the selection of patients for treatment and the drugs that can be used to treat these patients, as well as the treatment of hepatitis B in special populations. The present document should be read in conjunction with the companion document on the management of chronic hepatitis C.
Insights
This 2007 consensus conference provides updated guidelines for managing viral hepatitis in Canada. It addresses new treatments, risk assessment, and Canadian-specific barriers to patient care for hepatitis B and C.
Area of Science:
- Hepatology
- Infectious Diseases
- Clinical Guidelines
Background:
- The 2007 consensus development conference convened experts to update management strategies for viral hepatitis.
- New antiviral agents and updated risk assessment data necessitated a review of previous guidelines.
Framework:
- Guidelines focus on patient selection for antiviral therapy.
- Recommendations cover drug choices for treating viral hepatitis.
- Special populations with hepatitis B require tailored management approaches.
Implementation:
- Identified unique structural barriers within the Canadian healthcare system hindering optimal patient management.
- Emphasized the need for physicians to integrate new evidence into clinical practice.
- Promoted a collaborative approach between the Canadian Association for the Study of the Liver and the Association of Medical Microbiology and Infectious Disease Canada.
Implications:
- Aims to improve patient outcomes through evidence-based and accessible viral hepatitis management.
- Highlights the importance of addressing systemic issues to enhance care delivery.
- Serves as a critical resource for clinicians managing hepatitis B and C in Canada.
Related Concept Videos
01:25Hepatitis
01:28Viral Hepatitis I: Introduction
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations: